Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial

H. Poloczkova, J. Krejci, P. Hude, E. Ozabalova, J. Godava, T. Honek, V. Zampachova, I. Svobodova, T. Freiberger, L. Spinarova

. 2022 ; 123 (1) : 37-43.

Jazyk angličtina Země Slovensko

Typ dokumentu srovnávací studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22026095

INTRODUCTION: The indications for specific treatment in the cases of inflammatory cardiomyopathy are based on limited data from several small clinical trials. AIM: A comparison of the effect of two dose regimens of combined immunosuppressive therapy by adding them to conventional heart failure therapy and comparing them with conventional heart failure therapy alone in patients with inflammatory cardiomyopathy. METHODS AND STUDY POPULATION: We enrolled 20 patients; mean age 46.10±7.33 years, duration of symptoms <6 months, LVEF ≤40 %, NYHA class II–IV, with biopsy‐proven myocarditis. Patients were randomly separated into groups treated with immunosuppressive therapy in addition to conventional heart failure therapy or to a group treated with conventional heart failure therapy alone. Clinical and echocardiographic parameters were evaluated. RESULTS: The baseline values of LVEF in the group of immunosuppressive therapy (LVEF 22.3±4.7 %) were similar to those in the group treated with conventional heart failure therapy (LVEF 21.7±4.7 %; p=0.757). After twelve months there was no statistically significant difference in LVEF between the two studied groups (LVEF 33.7±9.5 % for the immunosuppressive therapy group and 41.3±13.0 % for the conventional therapy group; p=0.175). CONCLUSION: In our study population, we proved no positive effect of combined immunosuppressive therapy on the left ventricular function over 12 months. The main limitation of the study is the small number of enrolled patients (Tab. 4, Fig. 1, Ref. 35).

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22026095
003      
CZ-PrNML
005      
20230110133906.0
007      
ta
008      
221101s2022 xo d fs 000 0|eng||
009      
AR
024    0_
$a 10.4149/BLL_2022_006 $2 doi
035    __
$a (PubMed)34967656
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xo
100    1_
$a Poloczková, Hana $7 xx0121704 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
245    10
$a Effect of immunosuppressive therapy in inflammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial / $c H. Poloczkova, J. Krejci, P. Hude, E. Ozabalova, J. Godava, T. Honek, V. Zampachova, I. Svobodova, T. Freiberger, L. Spinarova
504    __
$a Literatura
520    9_
$a INTRODUCTION: The indications for specific treatment in the cases of inflammatory cardiomyopathy are based on limited data from several small clinical trials. AIM: A comparison of the effect of two dose regimens of combined immunosuppressive therapy by adding them to conventional heart failure therapy and comparing them with conventional heart failure therapy alone in patients with inflammatory cardiomyopathy. METHODS AND STUDY POPULATION: We enrolled 20 patients; mean age 46.10±7.33 years, duration of symptoms <6 months, LVEF ≤40 %, NYHA class II–IV, with biopsy‐proven myocarditis. Patients were randomly separated into groups treated with immunosuppressive therapy in addition to conventional heart failure therapy or to a group treated with conventional heart failure therapy alone. Clinical and echocardiographic parameters were evaluated. RESULTS: The baseline values of LVEF in the group of immunosuppressive therapy (LVEF 22.3±4.7 %) were similar to those in the group treated with conventional heart failure therapy (LVEF 21.7±4.7 %; p=0.757). After twelve months there was no statistically significant difference in LVEF between the two studied groups (LVEF 33.7±9.5 % for the immunosuppressive therapy group and 41.3±13.0 % for the conventional therapy group; p=0.175). CONCLUSION: In our study population, we proved no positive effect of combined immunosuppressive therapy on the left ventricular function over 12 months. The main limitation of the study is the small number of enrolled patients (Tab. 4, Fig. 1, Ref. 35).
650    _7
$a dospělí $7 D000328 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
650    _7
$a lidé středního věku $7 D008875 $2 czmesh
650    _7
$a výsledek terapie $7 D016896 $2 czmesh
650    17
$a imunosupresivní léčba $x metody $x škodlivé účinky $7 D007165 $2 czmesh
650    17
$a kardiomyopatie $x farmakoterapie $x terapie $7 D009202 $2 czmesh
650    _7
$a myokarditida $x farmakoterapie $x terapie $7 D009205 $2 czmesh
650    _7
$a prospektivní studie $7 D011446 $2 czmesh
650    _7
$a kombinovaná farmakoterapie $7 D004359 $2 czmesh
650    _7
$a prednison $x aplikace a dávkování $7 D011241 $2 czmesh
650    _7
$a azathioprin $x aplikace a dávkování $7 D001379 $2 czmesh
650    _7
$a tepový objem $x účinky léků $7 D013318 $2 czmesh
651    _7
$a Česká republika $7 D018153 $2 czmesh
655    _7
$a srovnávací studie $7 D003160 $2 czmesh
655    _7
$a randomizované kontrolované studie $7 D016449 $2 czmesh
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
700    1_
$a Krejčí, Jan $7 xx0204141 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Hude, Petr $7 stk2007393811 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Ozábalová, Eva $7 xx0107595 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Godava, Július $7 _AN028317 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Honek, Tomáš $7 xx0278697 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Žampachová, Víta $7 xx0088518 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Svobodová, Iva $7 xx0128976 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Freiberger, Tomáš, $d 1970- $7 xx0071641 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Špinarová, Lenka, $d 1961- $7 xx0061415 $u Department of Cardiovascular Diseases, St Anne ́s University Hospital and Masaryk University, Brno, Czech Republic
773    0_
$t Bratislavské lekárske listy $x 0006-9248 $g Roč. 123, č. 1 (2022), s. 37-43 $w MED00000845
856    41
$u http://www.elis.sk/download_file.php?product_id=7503&session_id=5hob67buame1h4jbqk1qin6737 $y plný text volně přístupný
910    __
$a ABA008 $b online $c 1067 $y p $z 0
990    __
$a 20221101161338 $b ABA008
991    __
$a 20230110133902 $b ABA008
999    __
$a ok $b bmc $g 1855389 $s 1177399
BAS    __
$a 3
BMC    __
$a 2022 $b 123 $c 1 $d 37-43 $i 0006-9248 $m Bratislavské lekárske listy $x MED00000845
LZP    __
$c NLK189 $d 20221217 $a NLK 2022-22/kv

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...